Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 21, 2020 - Issue 16
Submit an article Journal homepage
431
Views
7
CrossRef citations to date
0
Altmetric
Drug Evaluation

Evaluating entrectinib as a treatment option for non-small cell lung cancer

Jiyun LeeDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
,
Sehhoon ParkDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
,
Hyun Ae JungDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
,
Jong-Mu SunDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
,
Se-Hoon LeeDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
,
Jin Seok AhnDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
,
Keunchil ParkDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
&
Myung-Ju AhnDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaCorrespondence[email protected]
 show all
Pages 1935-1942 | Received 13 May 2020, Accepted 17 Jul 2020, Published online: 31 Jul 2020

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Ruggero Lasala, Andrea Zovi, Valentina Isgrò, Alessia Romagnoli, Felice Musicco & Fiorenzo Santoleri. (2023) Time to treatment discontinuation in first-line non-small cell lung carcinoma: an overview. Current Medical Research and Opinion 0:0, pages 1-10.
Read now

Articles from other publishers (6)

Mahmood Araghi, Reza Mannani, Ali Heidarnejad maleki, Adel Hamidi, Samaneh Rostami, Salar Hozhabri Safa, Fatemeh Faramarzi, Sahar Khorasani, Mina Alimohammadi, Safa Tahmasebi & Reza Akhavan-Sigari. (2023) Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell International 23:1.
Crossref
Hind M. Osman & Meral Tuncbilek. (2022) Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusionpositive, Recurrent or Advanced Solid Tumors. Current Medicinal Chemistry 29:15, pages 2602-2616.
Crossref
Diego Kauffmann-Guerrero & Amanda Tufman. (2022) Rare driver alterations in nonsmall cell lung cancer: novel targeted drugs. Current Opinion in Oncology 34:1, pages 77-82.
Crossref
Sara Elena Rebuzzi, Lodovica Zullo, Giovanni Rossi, Massimiliano Grassi, Veronica Murianni, Marco Tagliamento, Arsela Prelaj, Simona Coco, Luca Longo, Maria Giovanna Dal Bello, Angela Alama, Chiara Dellepiane, Elisa Bennicelli, Umberto Malapelle & Carlo Genova. (2021) Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences 22:5, pages 2625.
Crossref
Ilaria Guerriero, Gianni Monaco, Vincenzo Coppola & Arturo Orlacchio. (2020) Serum and Glucocorticoid-Inducible Kinase 1 (SGK1) in NSCLC Therapy. Pharmaceuticals 13:11, pages 413.
Crossref
Alberto D’Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow & Giandomenico Roviello. (2020) Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. Cancers 12:11, pages 3293.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.